A2A Pharmaceuticals
A2A Pharmaceuticals is a clinical stage oncology company focused on leveraging proprietary computational systems, including AI, to accelerate the development of novel drug alternatives for life-threatening diseases such as cancer, bacterial infections, and muscular dystrophy. They utilize the SCULPT platform for drug design, targeting challenging protein-protein interactions and developing innovative medicines through a strong pipeline of programs in different preclinical stages.
Industries
Nr. of Employees
small (1-50)
A2A Pharmaceuticals
Products
MLL–menin inhibitor program (clinical-stage)
Small-molecule inhibitors targeting the menin–MLL interaction developed for genomically defined leukemias and select solid tumors; program entered clinical development in 2021 in collaboration with a partner.
TACC3 PPI inhibitor (AO‑252) — Phase I clinical candidate
First-in-class small-molecule inhibitor targeting TACC3 under Phase I dose-escalation evaluation in ovarian, triple-negative breast and endometrial cancer; reported tumor reductions and ongoing dose escalation.
KRAS degrader program (preclinical)
Program developing small-molecule degrader approaches intended to address a broad range of KRAS mutations by degrading the KRAS protein rather than relying on mutation-specific inhibition.
TYK2 pseudokinase inhibitor program (preclinical)
Small-molecule program targeting the pseudokinase domain of TYK2 to modulate interferon and interleukin signaling pathways for autoimmune indications while aiming to reduce off-target toxicity.
YAP–TEAD inhibitor/degrader program (preclinical)
Small-molecule program aiming to inhibit or degrade YAP–TEAD interactions in the Hippo signaling pathway for oncology indications, using iterative computational design to address challenging target topology.
Antibacterial programs targeting gram-negative pathogens (preclinical)
Small-molecule antibiotic discovery programs using bioinformatic target selection and computational design to identify novel targets and generate antibiotic-like candidate molecules intended to minimize efflux and resistance.
MLL–menin inhibitor program (clinical-stage)
Small-molecule inhibitors targeting the menin–MLL interaction developed for genomically defined leukemias and select solid tumors; program entered clinical development in 2021 in collaboration with a partner.
TACC3 PPI inhibitor (AO‑252) — Phase I clinical candidate
First-in-class small-molecule inhibitor targeting TACC3 under Phase I dose-escalation evaluation in ovarian, triple-negative breast and endometrial cancer; reported tumor reductions and ongoing dose escalation.
KRAS degrader program (preclinical)
Program developing small-molecule degrader approaches intended to address a broad range of KRAS mutations by degrading the KRAS protein rather than relying on mutation-specific inhibition.
TYK2 pseudokinase inhibitor program (preclinical)
Small-molecule program targeting the pseudokinase domain of TYK2 to modulate interferon and interleukin signaling pathways for autoimmune indications while aiming to reduce off-target toxicity.
YAP–TEAD inhibitor/degrader program (preclinical)
Small-molecule program aiming to inhibit or degrade YAP–TEAD interactions in the Hippo signaling pathway for oncology indications, using iterative computational design to address challenging target topology.
Antibacterial programs targeting gram-negative pathogens (preclinical)
Small-molecule antibiotic discovery programs using bioinformatic target selection and computational design to identify novel targets and generate antibiotic-like candidate molecules intended to minimize efflux and resistance.
Services
Computational drug design and collaborative lead discovery
Provision of computationally driven lead discovery services that generate target-specific libraries, apply iterative optimization and ADMET filtering, and partner with external organizations for preclinical development.
Computational drug design and collaborative lead discovery
Provision of computationally driven lead discovery services that generate target-specific libraries, apply iterative optimization and ADMET filtering, and partner with external organizations for preclinical development.
Expertise Areas
- Computational drug design and AI-driven lead discovery
- Protein–protein interaction inhibitor development
- Medicinal chemistry and small-molecule optimization
- Preclinical efficacy testing (PDX and organoids)
Key Technologies
- Fragment-based computational design
- Artificial intelligence / machine learning for molecular design
- ADMET prediction and in silico filtering
- Protein–protein interaction targeting